Renal Biomarkers Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Renal Biomarkers Market By Biomarker Type (Functional Biomarkers, Up-Regulated Proteins, Others ), By Diagnostic Technique (Particle enhanced turbidimetric immunoassay, Chemiluminescent enzyme immunoassay, Enzyme linked immunosorbent assay, Colorimetric assay, Liquid chromatography), By End User (Hospitals, Outpatient Clinics, Research Centers, Diagnostic Labs), and Geography 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global renal biomarkers market size valued USD 1042.1 billion by 2020 and expected to reach USD 1454.08 billion by 2027, at a CAGR of 6.8% during the forecast period 2021-2027. Renal diseases are one of the major cause of death in geriatric population. Renal biomarkers are measurable indicators used to screening, monitoring, and diagnosing the activity of renal diseases by determining their blood and urine levels. The biomarkers are administered into kidneys to determine the renal functions. The early diagnosis of renal diseases helps to take proper treatment before the irreversible damage of kidneys.

Renal Biomarkers Market

MARKET SUMMARY
-
6.8% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 6.8%
  • Largest Market– Europe
  • Fastest Growing Market– North-America

Renal Biomarkers Market

  • The report on global renal biomarkers market gives historical, current and future market sizes (US$ Bn) based on biomarker type, diagnostic technique, by end user and region.
  • renal biomarkers market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Merck Millipore
  • Thermo Fisher Scientific Inc
  • Hoffmann-La Roche Ag
  • Abbott Molecular Inc
  • Beckman Coulter Inc
Renal Biomarkers Market

Drivers And Restraints

Increase in the prevalence of renal diseases due to rise in hypertension and diabetes in elderly patients is a major factor fuel the renal biomarkers market. Rise in geriatric population, increase in the R&D for the development of novel renal biomarkers, and using of renal biomarkers in preclinical and clinical trials to determine the safety of new drugs are anticipated to propel the market. However, stringent regulatory scenario, lack of specificity and sensitivity in current renal biomarkers, and lack of favorable reimbursement policies are anticipated to impede the growth of renal biomarkers market.


North-America got significant share

Renal Biomarkers Market

North America renal biomarkers market is expected to expand at significant CAGR due to its raising ageing population along with increased prevalence of renal disorders. The state-of-art healthcare infrastructure, and favorable reimbursement policies are expected to enhance the growth of renal biomarkers market. The existence of the manufacturers in large number, surge in R&D investments are expected to fuel the growth of market. The well established distribution channels further enhance the growth of the market. Europe market is anticipated to offer enormous opportunities for the market players plunged in market. Asia Pacific market is led by China, Japan, and India due to increasing geriatric population coupled with increased prevalence of renal disorders.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In December 2017, Thermo Fisher Scientific Completes Acquisition of Phenom-World.

Key

Key Features of the Report

Renal Biomarkers Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Merck Millipore (U.S)
  • Thermo Fisher Scientific Inc (U.S)
  • Hoffmann-La Roche Ag (Switzerland)
  • Abbott Molecular Inc (U.S)
  • Beckman Coulter Inc (U.S)
  • Astute Medical Inc (U.S)
  • Randox Laboratories Ltd (Ireland)

Description

The global renal biomarkers market size valued USD 1042.1 billion by 2020 and expected to reach USD 1454.08 billion by 2027, at a CAGR of 6.8% during the forecast period 2021-2027. Renal diseases are one of the major cause of death in geriatric population. Renal biomarkers are measurable indicators used to screening, monitoring, and diagnosing the activity of renal diseases by determining their blood and urine levels. The biomarkers are administered into kidneys to determine the renal functions. The early diagnosis of renal diseases helps to take proper treatment before the irreversible damage of kidneys.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX